| ￥1800 | |
| Z03839 | |
|
|
|
|
|
|
|
|
|
| Species | Human | ||||
| Protein Construction |
|
||||
| Purity |
> 95% as determined by Bis-Tris PAGE > 95% as determined by HPLC |
||||
| Endotoxin Level | Less than 1EU per μg by the LAL method. | ||||
| Biological Activity | Immobilized TROP-2/TACSTD2, His, Human (Cat.No.: Z03839) at 0.5 μg/ml (100μl/Well) on the plate can bind Anti-TROP-2 Antibody. | ||||
| Expression System | HEK293 | ||||
| Theoretical Molecular Weight | 28.9 kDa | ||||
| Apparent Molecular Weight | Due to glycosylation, the protein migrates to 40-60 kDa based on Bis-Tris PAGE result. | ||||
| Formulation | Lyophilized from a 0.22 μm filtered solution in PBS, pH 7.4. | ||||
| Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. | ||||
| Storage & Stability | Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background | Trop-2 (Tumor-associated calcium signal transducer 2) is also known as epithelial glycoprotein-1 antigen (EGP-1). It is encoded by the TACSTD2 gene. The mutations of Trop-2 gene cause an autosomal recessive disorder. Trop-2 causes cancer cell growth, proliferation, invasion, migration, and survival of cancer cells |
| Synonyms | EGP1; EGP-1; TROP2; GA733-1; gp50; T16; TACSTD2; TROP-2; M1S1; TACD2 |
For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.
